z-logo
Premium
Optimal Conditions to Induce Rat Adrenal Medullary Changes, Such as Pheochromocytoma, by Nicotine
Author(s) -
Saiko Yasushi,
Homma Yukio,
Kawabe Kazuki,
Aso Yoshio
Publication year - 1998
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1998.tb00415.x
Subject(s) - nicotine , adrenal medulla , endocrinology , catecholamine , epinephrine , medicine , pheochromocytoma , adrenal gland , metanephrine , chromaffin cell , medulla
Background: Nicotine‐induced adrenal medullary hypertrophy in rats has been suggested to be a model for pheochromocytoma. Study conditions for proving such an assertion, however, have not been optimized. Methods: Studies on strain difference, dose dependency, and the time course of catecholamine metabolism in response to nicotine treatment were conducted. Under the putative optimal experimental conditions, metabolic and histologic changes in the adrenal medulla were investigated. Results: Male Wistar rats treated with a maximum dose of 4 mg/kg per day of nicotine for 9 weeks, including a 2‐week lead‐in period, developed highly consistent changes in the adrenal medulla. Concerning metabolic indices, the norepinephrine content of the adrenal and the urinary excretion of epinephrine and metanephrine were significantly elevated. Hyperplastic and hyperactive states of the adrenal medulla were also indicated by a morphometric analysis on electron microscopic figures. These showed an enlarged cytoplasmic area, the development of a rough‐surfaced endoplasmic reticulum, and an increased number and density of intracellular catecholamine granules. The metabolic changes were found to reverse 3 weeks after the cessation of nicotine administration. Conclusion: These results provide better‐defined experimental conditions for an animal model of pheochromocytoma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here